{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T12:07:38Z","timestamp":1794226058449,"version":"4.8.0"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":1782,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s13311-018-0670-z","type":"journal-article","created":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T16:49:14Z","timestamp":1537807754000},"page":"1006-1017","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"title":["Statin-Associated Muscle Disease: Advances in Diagnosis and Management"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6032-3368","authenticated-orcid":false,"given":"Beth A.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-018-0670-z_bib1","author":"National Center for Health Statistics"},{"key":"10.1007\/s13311-018-0670-z_bib2","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1007\/s13311-018-0670-z_bib3","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1007\/s13311-018-0670-z_bib4","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1056\/NEJMoa1315665","article-title":"Application of new cholesterol guidelines to a population-based sample","volume":"370","author":"Pencina","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-018-0670-z_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190688","article-title":"Treatment gaps and potential cardiovascular risk reduction from expanded statin use in the US and England","volume":"13","author":"Ueda","year":"2018","journal-title":"PLoS One"},{"key":"10.1007\/s13311-018-0670-z_bib6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jacl.2012.06.006","article-title":"Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting","volume":"7","author":"Cziraky","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib7","doi-asserted-by":"crossref","first-page":"61C","DOI":"10.1016\/j.amjcard.2005.12.011","article-title":"Statin safety: an assessment using an administrative claims database","volume":"97","author":"Cziraky","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3233\/JND-170282","article-title":"Anti-HMGCR Myopathy","volume":"5","author":"Mohassel","year":"2018","journal-title":"J Neuromuscul Dis"},{"key":"10.1007\/s13311-018-0670-z_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0670-z_bib10","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1007\/s13311-018-0670-z_bib11","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.autrev.2016.07.023","article-title":"Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study","volume":"15","author":"Musset","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1007\/s13311-018-0670-z_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib13","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/pds.3787","article-title":"Association between trajectories of statin adherence and subsequent cardiovascular events","volume":"24","author":"Franklin","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1007\/s13311-018-0670-z_bib14","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.jacc.2016.12.036","article-title":"Statin Intolerance and Risk of Coronary Heart Events and All-Cause Mortality Following Myocardial Infarction","volume":"69","author":"Serban","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib15","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacl.2016.10.003","article-title":"Clinical and economic consequences of statin intolerance in the United States: Results from an integrated health system","volume":"11","author":"Graham","year":"2017","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.amjcard.2011.01.052","article-title":"Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations","volume":"107","author":"Pittman","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib17","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2013the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1007\/s13311-018-0670-z_bib18","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","article-title":"Prevalence of musculoskeletal pain and statin use","volume":"23","author":"Buettner","year":"2008","journal-title":"J Gen Intern Med"},{"key":"10.1007\/s13311-018-0670-z_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ahj.2014.03.019","article-title":"A systematic review of statin-induced muscle problems in clinical trials","volume":"168","author":"Ganga","year":"2014","journal-title":"Am Heart J"},{"key":"10.1007\/s13311-018-0670-z_bib20","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1007\/s13311-018-0670-z_bib21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.atherosclerosis.2014.12.016","article-title":"A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy","volume":"238","author":"Taylor","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1007\/s13311-018-0670-z_bib22","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"},{"key":"10.1007\/s13311-018-0670-z_bib23","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","author":"Tobert","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib24","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2017.7582","article-title":"Nocebo Effect May Account for Statin Adverse Events","volume":"317","author":"Slomski","year":"2017","journal-title":"JAMA"},{"key":"10.1007\/s13311-018-0670-z_bib25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-016604","article-title":"Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care","volume":"7","author":"Herrett","year":"2017","journal-title":"BMJ Open"},{"key":"10.1007\/s13311-018-0670-z_bib26","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.1016\/j.jacl.2014.03.004","article-title":"The National Lipid Association's Muscle Safety Expert,Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update","volume":"8","author":"Rosenson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib27","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.jacc.2017.07.752","article-title":"Optimizing Cholesterol Treatment in Patients With Muscle Complaints","volume":"70","author":"Rosenson","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10557-016-6655-4","article-title":"Clinical Profile of Statin Intolerance in the Phase 3 GAUSS-2 Study","volume":"30","author":"Cho","year":"2016","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1007\/s13311-018-0670-z_bib29","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients","volume":"30","author":"Cham","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1007\/s13311-018-0670-z_bib30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1517\/14740338.5.5.651","article-title":"Statins and myotoxicity: a therapeutic limitation","volume":"5","author":"Tiwari","year":"2006","journal-title":"Expert Opin Drug Saf"},{"key":"10.1007\/s13311-018-0670-z_bib31","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.cjca.2016.01.003","article-title":"Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Canadian Consensus Working Group Update (2016)","volume":"32","author":"Mancini","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2013.07.001","article-title":"Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance","volume":"230","author":"Ballard","year":"2013","journal-title":"Atherosclerosis"},{"key":"10.1007\/s13311-018-0670-z_bib33","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijcard.2016.02.028","article-title":"Increased creatine kinase with statin treatment may identify statin-associated muscle symptoms","volume":"209","author":"Taylor","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib34","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1007\/s13311-018-0670-z_bib35","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/0026-0495(91)90039-Y","article-title":"Effects of exercise and lovastatin on serum creatine kinase activity","volume":"40","author":"Thompson","year":"1991","journal-title":"Metabolism"},{"key":"10.1007\/s13311-018-0670-z_bib36","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2007.12.029","article-title":"The creatine kinase response to eccentric exercise with atorvastatin 10 mg or 80 mg","volume":"200","author":"Kearns","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1007\/s13311-018-0670-z_bib37","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib38","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1007\/s13311-018-0670-z_bib39","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/MOL.0b013e32833c1edf","article-title":"The effects of statins on skeletal muscle strength and exercise performance","volume":"21","author":"Krishnan","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib40","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/qjmed\/hcp093","article-title":"Statin therapy, muscle function and falls risk in community-dwelling older adults","volume":"102","author":"Scott","year":"2009","journal-title":"QJM"},{"key":"10.1007\/s13311-018-0670-z_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.jacl.2015.01.004","article-title":"Changes in muscle strength in individuals with statin-induced myopathy: A summary of 3 investigations","volume":"9","author":"Panza","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MOL.0000000000000174","article-title":"Muscle-related side-effects of statins: from mechanisms to evidence-based solutions","volume":"26","author":"Taylor","year":"2015","journal-title":"Curr Opin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib43","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1113\/jphysiol.2014.285577","article-title":"Statin myalgia is not associated with reduced muscle strength, mass or protein turnover in older male volunteers, but is allied with a slowing of time to peak power output, insulin resistance and differential muscle mRNA expression","volume":"593","author":"Mallinson","year":"2015","journal-title":"J Physiol"},{"key":"10.1007\/s13311-018-0670-z_bib44","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1152\/japplphysiol.00107.2011","article-title":"Atorvastatin treatment reduces exercise capacities in rats: involvement of mitochondrial impairments and oxidative stress","volume":"111","author":"Bouitbir","year":"2011","journal-title":"J Appl Physiol (1985)"},{"key":"10.1007\/s13311-018-0670-z_bib45","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1089\/ars.2014.6190","article-title":"Statins Trigger Mitochondrial Reactive Oxygen Species-Induced Apoptosis in Glycolytic Skeletal Muscle","volume":"24","author":"Bouitbir","year":"2016","journal-title":"Antioxid Redox Signal"},{"key":"10.1007\/s13311-018-0670-z_bib46","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/mus.22081","article-title":"Transcriptional deficits in oxidative phosphorylation with statin myopathy","volume":"44","author":"Hubal","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0670-z_bib47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.21847","article-title":"Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications","volume":"43","author":"Wu","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1007\/s13311-018-0670-z_bib48","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1249\/MSS.0b013e3181aae96b","article-title":"Metabolic myopathies: functional evaluation by analysis of oxygen uptake kinetics","volume":"41","author":"Grassi","year":"2009","journal-title":"Med Sci Sports Exerc"},{"key":"10.1007\/s13311-018-0670-z_bib49","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacc.2013.02.074","article-title":"Simvastatin impairs exercise training adaptations","volume":"62","author":"Mikus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1080\/00913847.2016.1135038","article-title":"Short-term cessation of statin therapy does not alter aerobic exercise performance in physically active middle-aged adults","volume":"44","author":"Ballard","year":"2016","journal-title":"Phys Sportsmed"},{"key":"10.1007\/s13311-018-0670-z_bib51","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10557-017-6723-4","article-title":"The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability","volume":"31","author":"Rosenson","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1007\/s13311-018-0670-z_bib52","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.jacc.2017.07.767","article-title":"Application of the Statin-Associated Muscle Symptoms-Clinical Index to a Randomized Trial onStatin Myopathy","volume":"70","author":"Taylor","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib53","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1007\/s13311-018-0670-z_bib54","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","article-title":"Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education","volume":"7","author":"Wei","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib55","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10557-018-6775-0","article-title":"Unmet Patient Need in Statin Intolerance: the Clinical Characteristics and Management","volume":"32","author":"Harrison","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1007\/s13311-018-0670-z_bib56","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.jacc.2016.02.071","article-title":"Statin-Associated Side Effects","volume":"67","author":"Thompson","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib57","first-page":"435","article-title":"Reversible muscle weakness in patients with vitamin D deficiency","volume":"167","author":"Ziambaras","year":"1997","journal-title":"West J Med"},{"key":"10.1007\/s13311-018-0670-z_bib58","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12603-010-0287-3","article-title":"Effect of vitamin D nutritional status on muscle function and strength in healthy women aged over sixty-five years","volume":"15","author":"Mastaglia","year":"2011","journal-title":"J Nutr Health Aging"},{"key":"10.1007\/s13311-018-0670-z_bib59","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1002\/jbmr.510","article-title":"Is vitamin D a determinant of muscle mass and strength?","volume":"26","author":"Marantes","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1007\/s13311-018-0670-z_bib60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2014.10.118","article-title":"Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients","volume":"178","author":"Michalska-Kasiczak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib61","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.reuma.2016.03.009","article-title":"Is there really a relationship between serum vitamin D (25OHD) levels and the musculoskeletal pain associated with statin intake? A systematic review","volume":"12","author":"Pereda","year":"2016","journal-title":"Reumatol Clin"},{"key":"10.1007\/s13311-018-0670-z_bib62","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.clinthera.2014.02.023","article-title":"Low vitamin D as a risk factor for the development of myalgia in patients taking high-dose simvastatin: a retrospective review","volume":"36","author":"Mergenhagen","year":"2014","journal-title":"Clin Ther"},{"key":"10.1007\/s13311-018-0670-z_bib63","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/bcpt.12482","article-title":"Low Vitamin D Levels and Genetic Polymorphism in the Vitamin D Receptor are Associated with Increased Risk of Statin-Induced Myopathy","volume":"118","author":"Ovesjo","year":"2016","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1007\/s13311-018-0670-z_bib64","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.atherosclerosis.2014.11.012","article-title":"Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study","volume":"238","author":"Morioka","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1007\/s13311-018-0670-z_bib65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/1947-2714.153919","article-title":"Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation","volume":"7","author":"Khayznikov","year":"2015","journal-title":"N Am J Med Sci"},{"key":"10.1007\/s13311-018-0670-z_bib66","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/1947-2714.179133","article-title":"Safety of 50,000-100,000 Units of Vitamin D3\/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance","volume":"8","author":"Jetty","year":"2016","journal-title":"N Am J Med Sci"},{"key":"10.1007\/s13311-018-0670-z_bib67","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2265.2011.04321.x","article-title":"Muscle pain and serum creatine kinase are not associated with low serum 25(OH) vitamin D levels in patients receiving statins","volume":"77","author":"Kurnik","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.1007\/s13311-018-0670-z_bib68","first-page":"42","article-title":"Low plasma vitamin D levels and muscle-related adverse effects in statin users","volume":"16","author":"Eisen","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"10.1007\/s13311-018-0670-z_bib69","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1185\/03007995.2012.702102","article-title":"Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D","volume":"28","author":"Riphagen","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1007\/s13311-018-0670-z_bib70","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.atherosclerosis.2016.11.011","article-title":"Low vitamin D does not predict statin-associated muscle symptoms but is associated with transient increases in muscle damage and pain","volume":"256","author":"Taylor","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1007\/s13311-018-0670-z_bib71","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1007\/s13311-018-0670-z_bib72","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10557-017-6738-x","article-title":"Primary Care Physician Perspectives on Barriers to Statin Treatment","volume":"31","author":"Tanner","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1007\/s13311-018-0670-z_bib73","doi-asserted-by":"crossref","first-page":"221","DOI":"10.7326\/M16-0838","article-title":"Continued Statin Prescriptions After Adverse Reactions and Patient Outcomes: A Cohort Study","volume":"167","author":"Zhang","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1007\/s13311-018-0670-z_bib74","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0197-3118.2005.04404.x","article-title":"Decreasing LDL cholesterol and medication cost with every-other-day statin therapy","volume":"8","author":"Juszczyk","year":"2005","journal-title":"Prev Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib75","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s10557-017-6743-0","article-title":"Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis","volume":"31","author":"Awad","year":"2017","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1007\/s13311-018-0670-z_bib76","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jacc.2016.03.519","volume":"68","author":"Lloyd-Jones","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib77","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacl.2015.08.006","article-title":"Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial","volume":"9","author":"Moriarty","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1007\/s13311-018-0670-z_bib78","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib79","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-018-0670-z_bib80","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jacc.2018.04.040","article-title":"The Role of Nutraceuticals in Statin Intolerant Patients","volume":"72","author":"Banach","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib81","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib82","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib83","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1007\/s13311-018-0670-z_bib84","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","article-title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy","volume":"47","author":"Bogsrud","year":"2013","journal-title":"Scand Cardiovasc J"},{"key":"10.1007\/s13311-018-0670-z_bib85","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1139\/cjpp-2012-0118","article-title":"Coenzyme Q(10) and selenium in statin-associated myopathy treatment","volume":"91","author":"Fedacko","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1007\/s13311-018-0670-z_bib86","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3810\/psm.2012.11.1991","article-title":"Impact of coenzyme Q-10 on parameters of cardiorespiratory fitness and muscle performance in older athletes taking statins","volume":"40","author":"Deichmann","year":"2012","journal-title":"Phys Sportsmed"},{"key":"10.1007\/s13311-018-0670-z_bib87","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.12659\/MSM.890777","article-title":"Coenzyme Q10 supplementation decreases statin-related mild-to-moderate muscle symptoms: a randomized clinical study","volume":"20","author":"Skarlovnik","year":"2014","journal-title":"Med Sci Monit"},{"key":"10.1007\/s13311-018-0670-z_bib88","first-page":"e212","article-title":"Effects of Coenzyme Q10 on Skeletal Muscle Oxidative Metabolism in Statin Users Assessed Using 31P Magnetic Resonance Spectroscopy: a Randomized Controlled Study","volume":"2","author":"Buettner","year":"2016","journal-title":"J Nat Sci"},{"key":"10.1007\/s13311-018-0670-z_bib89","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1515\/jbcpp-2016-0149","article-title":"Addition of omega-3 fatty acid and coenzyme Q10 to statin therapy in patients with combined dyslipidemia","volume":"28","author":"Toth","year":"2017","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"10.1007\/s13311-018-0670-z_bib90","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.mayocp.2014.08.021","article-title":"Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials","volume":"90","author":"Banach","year":"2015","journal-title":"Mayo Clin Proc"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-0670-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0670-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923010280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-0670-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T19:46:39Z","timestamp":1728675999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923010280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S1878747923010280"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-0670-z","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin-Associated Muscle Disease: Advances in Diagnosis and Management","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-0670-z","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}